Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.35 |
| ▸ | NOS1 | P29475 | 4/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922558 | 1.00 | NOS2 (0.35) | NOS2NOS1NOS3KMT2AALOX15 | |
| SCHEMBL4922553 | 1.00 | NOS2 (0.35) | NOS2NOS1NOS3KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL14831358 | 0.97 | NOS2 (0.34) | NOS2NOS1NOS3KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL14831359 | 0.97 | NOS2 (0.34) | NOS2NOS1NOS3KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL22290093 | 0.97 | NOS2 (0.34) | NOS2NOS1NOS3KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL4141642 | 0.97 | NOS2 (0.34) | NOS2NOS1NOS3KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL4141639 | 0.97 | NOS2 (0.34) | NOS2NOS1NOS3KMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL22290092 | 0.97 | NOS2 (0.34) | NOS2NOS1NOS3KMT2AALOX15 | |
| SCHEMBL9703082 | 0.90 | NOS2 (0.47) | NOS2NOS1NOS3KMT2AALOX15 | |
| SCHEMBL29008680 | 0.90 | NOS2 (0.47) | NOS2NOS1NOS3KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265611-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | Consorcio Centro de Investigación Biomédica en Red, M.P. (ES) | 2022-08-25 | — | — | US | claimed |
| EP-4004541-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) (ES) | 2022-06-01 | — | — | EP | claimed |
| CN-114269722-A | Ergothioneine, S-methyl-ergothioneine and uses thereof | 贝尔维奇生物医学研究所(伊迪贝尔) | 2022-04-01 | — | — | CN | claimed |
| WO-2021018774-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) (ES) | 2021-02-04 | — | — | WO | claimed |
| EP-0378432-B1 | Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation | RICHTER GEDEON VEGYESZET (HU) | 1995-04-05 | — | — | EP | claimed |
| EP-0378432-A2 | Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1990-07-18 | — | — | EP | claimed |
| US-12486241-B2 | Cystine diamide analogs for cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-12-02 | — | — | US | disclosed |
| US-12391661-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-08-19 | — | — | US | disclosed |
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4072537-A1 | CYSTINE DIAMIDE ANALOGS FOR CYSTINURIA | Rutgers, the State University of New Jersey (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-115103669-A | Cystine diamide analogs for cystinuria | 新泽西鲁特格斯州立大学 | 2022-09-23 | — | — | CN | disclosed |
| US-9428453-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428453-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-07-03 | — | — | US | disclosed |
| EP-0378432-B1 | Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation | RICHTER GEDEON VEGYESZET (HU) | 1995-04-05 | — | — | EP | disclosed |
| US-5093320-A | Immunosuppressants | RICHTER GEDEON VEGYESZETI GYAR R. T. (HU) | 1992-03-03 | — | — | US | disclosed |
| EP-0378432-A2 | Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486241-B2 | Cystine diamide analogs for cystinuria | CTH, CBS, SLC7A11 | NOS2 1945/4885NOS1 1583/4885NOS3 1505/4885 |
| US-20140187546-A1 | Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria | CTH, CBS, SLC6A12 | NOS2 1102/4885NOS1 949/4885NOS3 827/4885 |
| US-20220265611-A1 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF | BHMT2, GNMT, BHMT | NOS2 1750/4885NOS1 1773/4885NOS3 1545/4885 |
| US-12391661-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | CTH, CBS, SLC6A12 | NOS2 1102/4885NOS1 949/4885NOS3 827/4885 |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | CTH, CBS, SLC6A12 | NOS2 1102/4885NOS1 949/4885NOS3 827/4885 |
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | CTH, CBS, SLC7A11 | NOS2 1945/4885NOS1 1583/4885NOS3 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.